BACKGROUND: Low muscle mass has been associated with chemotherapy toxicity. We conducted this prospective study to evaluate the effects of body composition on the occurrence of toxicity in phase I trials. PATIENTS AND METHODS: Patients were consecutively enrolled irrespective of the type of tumor or the type of drug. The Skeletal Muscle Index (SMIndex) and visceral and subcutaneous adipose tissue were assessed with computed tomography imaging by measuring cross-sectional areas of the tissues (cm(2)/m(2)). Dose-limiting toxicity (DLT) corresponded to toxicities occurring during the 1(st) cycle that necessitated dose reduction, postponement or interruption of drug administration and severe toxicity events (STE) corresponded to DLT or permanent treatment withdrawal due to toxicity. RESULTS: 93 patients were evaluated. Ten percent of patients experienced DLT and had a lower SMIndex: 40.8 ± 4.6 vs. 48.1 ± 9.6 cm(2)/m(2) (p = 0.01). STE occurred in 14 % of the patients. The only factor associated with STE was a low SMIndex: 42.4 ± 5.8 vs. 48.4 ± 9.7 cm(2)/m(2) (p = 0.02). STE were observed in 25.5 % of the patients when the SMIndex was below the median value compared to 6.5 % of patients with a high SMIndex (p = 0.02). CONCLUSION: Muscle mass is a critical predictor of severe toxicity events in phase I patients, suggesting that sarcopenia may be considered in assessing patients for eligibility of phase-1 studies.
BACKGROUND: Low muscle mass has been associated with chemotherapy toxicity. We conducted this prospective study to evaluate the effects of body composition on the occurrence of toxicity in phase I trials. PATIENTS AND METHODS: Patients were consecutively enrolled irrespective of the type of tumor or the type of drug. The Skeletal Muscle Index (SMIndex) and visceral and subcutaneous adipose tissue were assessed with computed tomography imaging by measuring cross-sectional areas of the tissues (cm(2)/m(2)). Dose-limiting toxicity (DLT) corresponded to toxicities occurring during the 1(st) cycle that necessitated dose reduction, postponement or interruption of drug administration and severe toxicity events (STE) corresponded to DLT or permanent treatment withdrawal due to toxicity. RESULTS: 93 patients were evaluated. Ten percent of patients experienced DLT and had a lower SMIndex: 40.8 ± 4.6 vs. 48.1 ± 9.6 cm(2)/m(2) (p = 0.01). STE occurred in 14 % of the patients. The only factor associated with STE was a low SMIndex: 42.4 ± 5.8 vs. 48.4 ± 9.7 cm(2)/m(2) (p = 0.02). STE were observed in 25.5 % of the patients when the SMIndex was below the median value compared to 6.5 % of patients with a high SMIndex (p = 0.02). CONCLUSION: Muscle mass is a critical predictor of severe toxicity events in phase I patients, suggesting that sarcopenia may be considered in assessing patients for eligibility of phase-1 studies.
Authors: Carla M M Prado; Vickie E Baracos; Linda J McCargar; Tony Reiman; Marina Mourtzakis; Katia Tonkin; John R Mackey; Sheryl Koski; Edith Pituskin; Michael B Sawyer Journal: Clin Cancer Res Date: 2009-04-07 Impact factor: 12.531
Authors: Noelle K LoConte; Maureen Smith; Dona Alberti; Jeffrey Bozeman; James F Cleary; Ashley N Setala; Geoff Wodtke; George Wilding; Kyle D Holen Journal: Cancer Chemother Pharmacol Date: 2009-08-01 Impact factor: 3.333
Authors: Jeffrey A Meyerhardt; Joel E Tepper; Donna Niedzwiecki; Donna R Hollis; A David McCollum; Denise Brady; Michael J O'Connell; Robert J Mayer; Bernard Cummings; Christopher Willett; John S Macdonald; Al B Benson; Charles S Fuchs Journal: J Clin Oncol Date: 2004-02-15 Impact factor: 44.544
Authors: A Italiano; C Massard; R Bahleda; A-L Vataire; E Deutsch; N Magné; J-P Pignon; G Vassal; J-P Armand; J-C Soria Journal: Ann Oncol Date: 2007-11-27 Impact factor: 32.976
Authors: O Huillard; O Mir; M Peyromaure; C Tlemsani; J Giroux; P Boudou-Rouquette; S Ropert; N Barry Delongchamps; M Zerbib; F Goldwasser Journal: Br J Cancer Date: 2013-03-05 Impact factor: 7.640
Authors: S Gérard; D Bréchemier; A Lefort; S Lozano; G Abellan Van Kan; T Filleron; L Mourey; C Bernard-Marty; M E Rougé-Bugat; V Soler; B Vellas; M Cesari; Y Rolland; L Balardy Journal: J Nutr Health Aging Date: 2016 Impact factor: 4.075
Authors: Philippe Atlan; Mohamed Amine Bayar; Emilie Lanoy; Benjamin Besse; David Planchard; Jordy Ramon; Bruno Raynard; Sami Antoun Journal: Support Care Cancer Date: 2017-06-08 Impact factor: 3.603
Authors: David R Fogelman; J Morris; L Xiao; M Hassan; S Vadhan; M Overman; S Javle; R Shroff; G Varadhachary; R Wolff; L Vence; A Maitra; C Cleeland; X S Wang Journal: Support Care Cancer Date: 2017-01-22 Impact factor: 3.603
Authors: Raafi Ali; Vickie E Baracos; Michael B Sawyer; Laurent Bianchi; Sarah Roberts; Eric Assenat; Caroline Mollevi; Pierre Senesse Journal: Cancer Med Date: 2016-01-27 Impact factor: 4.452